- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00070837
MLN2704 in Subjects With Metastatic Androgen-Independent Prostate Cancer
July 12, 2007 updated by: Millennium Pharmaceuticals, Inc.
A Phase 1/2 Dose Escalation Trial of Multiple Doses of MLN2704 (DM1 Conjugated Monoclonal Antibody MLN591) in Subjects With Metastatic Androgen-Independent Prostate Cancer
The purpose of the study is to determine the highest dose of MLN2704 that can be given multiple times safely to patients with prostate cancer, and to identify any side effects associated with taking the drug.
This study will also evaluate how MLN2704 is taken up, broken down and eliminated by the body.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment
46
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New York
-
New York, New York, United States, 10021
- Memorial Sloan-Kettering Cancer Center
-
New York, New York, United States, 10021
- Weill Medical College of Cornell University/ New York Presbyterian Hospital
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
- Duke University Medical Center, Box 3532
-
-
Ohio
-
Cleveland, Ohio, United States, 44195
- Cleveland Clinic, Taussig Cancer Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Histologic or cytologic diagnosis (recent or remote) of prostate adenocarcinoma
- Radiographic evidence (recent or remote) of metastatic prostate adenocarcinoma
- 18 years of age or older
Progressive prostate cancer as defined by the presence of one or more of the following despite castrate levels of testosterone (testosterone <50 ng/dL):
- Progressive tumor lesions (changes in the size of lymph nodes or parenchymal masses on physical examination or X-ray and CT scan or MRI)
- Progressive bone metastasis (presence of new lesion(s) on a bone scan)
- Progressive PSA levels (as defined in Section 3.6.1)
- Subjects who have received an anti-androgen must have shown progression of disease following discontinuation of the anti-androgen
- Subjects must remain on luteinizing hormone-releasing hormone (LHRH) analog therapy for the duration of the trial unless surgically castrate
- Agree to use an effective barrier method of contraception.
Exclusion criteria:
- Testosterone >50 ng/dL
- Use of corticosteroids and/or adrenal hormone inhibitors within 4 weeks of dosing
- Use of PC-SPES within 4 weeks of dosing
- Prior cytotoxic chemotherapy and/or radiation therapy within 6 weeks of dosing
- Use of anti-androgen therapy (eg, flutamide, bicalutamide, nilutamide) within 6 weeks of dosing
- Prior monoclonal antibody administration, including Prostascint®
- Peripheral neuropathy of > Grade 2, as defined by the NCI Common Toxicity Criteria for Adverse Events (NCI CTCAE)
- History of CNS metastasis, including incompletely treated epidural disease
- History of Hepatitis B or C
- History of seizure disorder requiring active treatment and/or stroke
- History of HIV infection
- Platelet count <100,000/mm3
- Absolute neutrophil count (ANC) <1,500/mm3
- Hematocrit <27 percent
- Abnormal coagulation profile (elevated PT, and/or INR, PTT)
- Serum creatinine >2.0 mg/dL, or creatinine clearance <60 mL/min if serum creatinine >2.0 mg/dL
- AST or ALT >1.5 x ULN
- Bilirubin (total) >1.25 x ULN
- Serum calcium >12.5 mg/dL
- Active serious infection not controlled by antibiotics
- Active angina pectoris or NY Heart Association Class III-IV heart disease
- Karnofsky Performance Status <60%
- Life expectancy <6 months
- Other serious illness(es) involving the cardiac, respiratory, CNS, renal, hepatic or hematological organ systems that might preclude completion of this study or interfere with determination of causality of any adverse effects experienced in this study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2003
Study Completion
October 1, 2004
Study Registration Dates
First Submitted
October 8, 2003
First Submitted That Met QC Criteria
October 10, 2003
First Posted (Estimate)
October 13, 2003
Study Record Updates
Last Update Posted (Estimate)
July 13, 2007
Last Update Submitted That Met QC Criteria
July 12, 2007
Last Verified
July 1, 2007
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- M59102-051
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prostatic Neoplasms
-
Australian and New Zealand Urogenital and Prostate...Peter MacCallum Cancer Centre, AustraliaRecruitingCastration Resistant Prostatic CancerAustralia
-
British Columbia Cancer AgencySanofi; Ozmosis Research Inc.UnknownMetastatic Castration-Resistant Prostatic CancerCanada, Australia
-
MacroGenicsRecruitingCastration-Resistant Prostatic Cancer | Androgen-Independent Prostatic Cancer | Androgen-Insensitive Prostatic Cancer | Androgen-Resistant Prostatic Cancer | Hormone Refractory Prostatic CancerSpain, Australia, Korea, Republic of, United States, France, Italy, Belgium, United Kingdom, Poland
-
Janssen Research & Development, LLCCompletedCastration-Resistant Prostatic NeoplasmsCanada, Belgium, United States, Spain, Netherlands, Italy, Russian Federation
-
Technische Universität DresdenRecruitingOligometastatic Disease | Prostatic Cancer, Castration-ResistantGermany
-
Yinghao SunNot yet recruitingCastration-Resistant Prostatic Cancer
-
Institut Claudius RegaudWithdrawnProstatic Cancer, Castration-ResistantFrance
-
Universität des SaarlandesRecruitingProstate Cancer Metastatic | Advanced Prostate Carcinoma | Castration Resistant Prostatic CancerGermany
-
University Hospital, GrenobleTerminatedCastration-resistant Prostate CancerFrance
-
Michael Graham PhD, MDUniversity of Iowa; Holden Comprehensive Cancer CenterActive, not recruitingProstate Cancer | Prostatic Neoplasms, Castration-Resistant | Prostatic Neoplasm | Prostatic Cancer Recurrent | Prostatic Cancer MetastaticUnited States
Clinical Trials on MLN2704 (DM1 conjugated monoclonal antibody MLN591)
-
Millennium Pharmaceuticals, Inc.CompletedProstate CancerUnited States
-
George W. Sledge Jr.National Cancer Institute (NCI)CompletedStage IV Breast Cancer | Recurrent Breast Carcinoma | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | HER2 Positive Breast Carcinoma | Stage III Breast CancerUnited States
-
NRG OncologyNational Cancer Institute (NCI)RecruitingRecurrent Salivary Gland Carcinoma | Stage III Major Salivary Gland Cancer AJCC v8 | Stage IV Major Salivary Gland Cancer AJCC v8 | Metastatic Salivary Gland Carcinoma | Unresectable Salivary Gland CarcinomaUnited States
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)RecruitingStage II Breast Cancer AJCC v6 and v7 | Stage IIA Breast Cancer AJCC v6 and v7 | Stage IIB Breast Cancer AJCC v6 and v7 | Stage III Breast Cancer AJCC v7 | Stage IIIA Breast Cancer AJCC v7 | Stage IIIB Breast Cancer AJCC v7 | Stage IIIC Breast Cancer AJCC v7 | Breast AdenocarcinomaUnited States
-
ECOG-ACRIN Cancer Research GroupNational Cancer Institute (NCI)RecruitingAnatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Prognostic Stage II Breast Cancer AJCC v8 | Prognostic Stage IIA Breast Cancer AJCC v8 | Prognostic Stage IIB Breast Cancer... and other conditionsUnited States, Puerto Rico
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)WithdrawnRecurrent Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Del(5q) | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) | Adult Acute Myeloid Leukemia With t(8... and other conditions
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)Approved for marketingRecurrent Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Del(5q) | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) | Adult Acute Myeloid Leukemia With t(8... and other conditionsUnited States
-
University of WashingtonPfizerRecruitingAcute Myeloid LeukemiaUnited States
-
Shanghai Fosun Pharmaceutical Industrial Development...Recruiting
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedRecurrent Neuroblastoma | Recurrent Rhabdomyosarcoma | Wilms Tumor | Recurrent Malignant Peripheral Nerve Sheath Tumor | Recurrent Synovial Sarcoma | Pleuropulmonary BlastomaUnited States